Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9NPJ1
UPID:
MKKS_HUMAN
Alternative names:
Bardet-Biedl syndrome 6 protein; McKusick-Kaufman/Bardet-Biedl syndromes putative chaperonin
Alternative UPACC:
Q9NPJ1; A8K7B0; D3DW18
Background:
The Molecular chaperone MKKS, also known as Bardet-Biedl syndrome 6 protein, plays a crucial role in protein folding with ATP hydrolysis. It is instrumental in the assembly of BBSome, a complex essential for ciliogenesis and vesicle transport to cilia, impacting limb, cardiac, and reproductive system development.
Therapeutic significance:
Given its involvement in McKusick-Kaufman syndrome and Bardet-Biedl syndrome 6, characterized by developmental disorders and congenital anomalies, targeting MKKS could offer novel therapeutic avenues for these genetic conditions.